Dr. Richard McFarland, PhD, MD, is Chief Regulatory Officer at ARMI | BioFabUSA, where he leads regulatory strategy to enable scalable, compliant manufacturing of advanced therapies. He brings more than 16 years of experience from the U.S. Food and Drug Administration (FDA/CBER), including over a decade as Associate Director of Policy for the Office of Tissues and Advanced Therapies. His work has shaped risk-based regulatory frameworks for regenerative medicine, tissue engineering, and advanced therapies, with a focus on supporting translation from discovery to commercial deployment.